Cargando…

Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis

Background: The β-Lactam Infusion Group (BLING) III study is a prospective, multicentre, open, phase 3 randomised controlled trial comparing continuous infusion with intermittent infusion of β-lactam antibiotics in 7000 critically ill patients with sepsis. Objective: To describe a statistical analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Billot, Laurent, Lipman, Jeffrey, Brett, Stephen J., De Waele, Jan J., Cotta, Menino Osbert, Davis, Joshua S., Finfer, Simon, Hammond, Naomi E., Knowles, Serena, McGuinness, Shay, Myburgh, John, Paterson, David L., Peake, Sandra, Rajbhandari, Dorrilyn, Rhodes, Andrew, Roberts, Jason A., Roger, Claire, Shirwadkar, Charudatt, Starr, Therese, Taylor, Colman, Dulhunty, Joel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692542/
https://www.ncbi.nlm.nih.gov/pubmed/38046078
http://dx.doi.org/10.51893/2021.3.OA4
_version_ 1785152964946558976
author Billot, Laurent
Lipman, Jeffrey
Brett, Stephen J.
De Waele, Jan J.
Cotta, Menino Osbert
Davis, Joshua S.
Finfer, Simon
Hammond, Naomi E.
Knowles, Serena
McGuinness, Shay
Myburgh, John
Paterson, David L.
Peake, Sandra
Rajbhandari, Dorrilyn
Rhodes, Andrew
Roberts, Jason A.
Roger, Claire
Shirwadkar, Charudatt
Starr, Therese
Taylor, Colman
Dulhunty, Joel M.
author_facet Billot, Laurent
Lipman, Jeffrey
Brett, Stephen J.
De Waele, Jan J.
Cotta, Menino Osbert
Davis, Joshua S.
Finfer, Simon
Hammond, Naomi E.
Knowles, Serena
McGuinness, Shay
Myburgh, John
Paterson, David L.
Peake, Sandra
Rajbhandari, Dorrilyn
Rhodes, Andrew
Roberts, Jason A.
Roger, Claire
Shirwadkar, Charudatt
Starr, Therese
Taylor, Colman
Dulhunty, Joel M.
author_sort Billot, Laurent
collection PubMed
description Background: The β-Lactam Infusion Group (BLING) III study is a prospective, multicentre, open, phase 3 randomised controlled trial comparing continuous infusion with intermittent infusion of β-lactam antibiotics in 7000 critically ill patients with sepsis. Objective: To describe a statistical analysis plan for the BLING III study. Methods: The statistical analysis plan was designed by the trial statistician and chief investigators and approved by the BLING III management committee before the completion of data collection. Statistical analyses for primary, secondary and tertiary outcomes and planned subgroup analyses are described in detail. Interim analysis by the Data Safety and Monitoring Committee (DSMC) has been conducted in accordance with a pre-specified DSMC charter. Results and conclusions: The statistical analysis plan for the BLING III study is published before completion of data collection and unblinding to minimise analysis bias and facilitate public access and transparent analysis and reporting of study findings. Trial registration:ClinicalTrials.gov Registry NCT03212990.
format Online
Article
Text
id pubmed-10692542
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106925422023-12-03 Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis Billot, Laurent Lipman, Jeffrey Brett, Stephen J. De Waele, Jan J. Cotta, Menino Osbert Davis, Joshua S. Finfer, Simon Hammond, Naomi E. Knowles, Serena McGuinness, Shay Myburgh, John Paterson, David L. Peake, Sandra Rajbhandari, Dorrilyn Rhodes, Andrew Roberts, Jason A. Roger, Claire Shirwadkar, Charudatt Starr, Therese Taylor, Colman Dulhunty, Joel M. Crit Care Resusc Original Article Background: The β-Lactam Infusion Group (BLING) III study is a prospective, multicentre, open, phase 3 randomised controlled trial comparing continuous infusion with intermittent infusion of β-lactam antibiotics in 7000 critically ill patients with sepsis. Objective: To describe a statistical analysis plan for the BLING III study. Methods: The statistical analysis plan was designed by the trial statistician and chief investigators and approved by the BLING III management committee before the completion of data collection. Statistical analyses for primary, secondary and tertiary outcomes and planned subgroup analyses are described in detail. Interim analysis by the Data Safety and Monitoring Committee (DSMC) has been conducted in accordance with a pre-specified DSMC charter. Results and conclusions: The statistical analysis plan for the BLING III study is published before completion of data collection and unblinding to minimise analysis bias and facilitate public access and transparent analysis and reporting of study findings. Trial registration:ClinicalTrials.gov Registry NCT03212990. Elsevier 2023-10-18 /pmc/articles/PMC10692542/ /pubmed/38046078 http://dx.doi.org/10.51893/2021.3.OA4 Text en © 2021 College of Intensive Care Medicine of Australia and New Zealand. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Billot, Laurent
Lipman, Jeffrey
Brett, Stephen J.
De Waele, Jan J.
Cotta, Menino Osbert
Davis, Joshua S.
Finfer, Simon
Hammond, Naomi E.
Knowles, Serena
McGuinness, Shay
Myburgh, John
Paterson, David L.
Peake, Sandra
Rajbhandari, Dorrilyn
Rhodes, Andrew
Roberts, Jason A.
Roger, Claire
Shirwadkar, Charudatt
Starr, Therese
Taylor, Colman
Dulhunty, Joel M.
Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
title Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
title_full Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
title_fullStr Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
title_full_unstemmed Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
title_short Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
title_sort statistical analysis plan for the bling iii study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692542/
https://www.ncbi.nlm.nih.gov/pubmed/38046078
http://dx.doi.org/10.51893/2021.3.OA4
work_keys_str_mv AT billotlaurent statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT lipmanjeffrey statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT brettstephenj statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT dewaelejanj statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT cottameninoosbert statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT davisjoshuas statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT finfersimon statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT hammondnaomie statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT knowlesserena statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT mcguinnessshay statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT myburghjohn statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT patersondavidl statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT peakesandra statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT rajbhandaridorrilyn statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT rhodesandrew statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT robertsjasona statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT rogerclaire statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT shirwadkarcharudatt statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT starrtherese statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT taylorcolman statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT dulhuntyjoelm statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis
AT statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis